Clinical Trials · NCT01648582
A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 774
- Start date
- Jul 2012
- Locations
- 30 sites, 4 countries
- Primary endpoint
- Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks